Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

Clinical trial NCT06726265 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06726265
Sponsor: Immutep S.A.S.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Start date: 2025-03-21
Primary completion: 2027-06-01
Enrollment: 756

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.